KURA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Kura Oncology Inc (KURA) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The positive clinical trial results, strong analyst ratings, and potential market opportunity for its assets outweigh the recent financial performance concerns and insider selling. The stock's current pre-market price of $9.23 presents a reasonable entry point given its long-term growth potential.
The MACD is positive and contracting, indicating a bullish trend. The RSI is neutral at 52.545, suggesting no overbought or oversold conditions. The stock is trading near its pivot level of $9.28, with key resistance at $9.836 and support at $8.724. Moving averages are converging, indicating a potential breakout.
Positive clinical trial results from the FIT-001 trial, showing a 44% objective response rate and a 94% disease control rate.
Strong analyst ratings with price targets significantly higher than the current price.
Potential market opportunity for ziftomenib and other assets in development.
Insider selling has increased by 178.01% over the last month.
Revenue dropped significantly by -67.83% YoY in Q4
Lack of recent congress trading data and no proprietary trading signals today.
In Q4 2025, revenue dropped by -67.83% YoY to $17.34M. However, net income improved significantly by 321.50% YoY to -$80.99M, and EPS increased by 318.18% YoY to -0.92. Gross margin slightly declined to 99.67%.
Analysts maintain a positive outlook with multiple Buy and Outperform ratings. Recent price targets range from $15 to $36, indicating significant upside potential from the current price. Analysts highlight the market opportunity for ziftomenib and other assets as key growth drivers.
